COPD - Nationale VersorgungsLeitlinien

84. Maesen BL, Westermann CJ, Duurkens VA, van den Bosch JM. Effects of formoterol in apparently
poorly reversible chronic obstructive pulmonary disease. Eur Respir J 1999;13(5):1103-8.
85. Jones PW,Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir
Crit Care Med 1997;155(4):1283-9.
86. Peach H,Pathy MS. Follow-up study of disability among elderly patients discharged from hospital
with exacerbations of chronic bronchitis. Thorax 1981;36(8):585-9.
87. Cazzola M, Imperatore F, Salzillo A, Di Perna F, Calderaro F, Imperatore A, Matera MG. Cardiac
effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac
arrhythmias and hypoxemia. Chest 1998;114(2):411-5.
88. Karpel JP, Pesin J, Greenberg D, Gentry E. A comparison of the effects of ipratropium bromide and
metaproterenol sulfate in acute exacerbations of COPD. Chest 1990;98(4):835-9.
89. Patrick DM, Dales RE, Stark RM, Laliberte G, Dickinson G. Severe exacerbations of COPD and
asthma. Incremental benefit of adding ipratropium to usual therapy. Chest 1990;98(2):295-7.
90. Braun SR, McKenzie WN, Copeland C, Knight L, Ellersieck M. A comparison of the effect of
ipratropium and albuterol in the treatment of chronic obstructive airway disease. Arch Intern Med
1989;149(3):544-7.
91. Tashkin DP, Ashutosh K, Bleecker ER, Britt EJ, Cugell DW, Cummiskey JM, DeLorenzo L, Gilman
MJ, Gross GN, Gross NJ. Comparison of the anticholinergic bronchodilator ipratropium bromide with
metaproterenol in chronic obstructive pulmonary disease. A 90-day multi-center study. Am J Med
1986;81(5A):81-90.
92. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more
effective than either agent alone. An 85-day multicenter trial. COMBIVENT Inhalation Aerosol Study
Group. Chest 1994;105(5):1411-9.
93. Rennard SI. Extended bronchodilator treatment in chronic obstructive pulmonary disease. Eur Respir
Rev 1996;6:282-6.
94. Gillissen A, Buhl R, Rabe KF, Vogelmeier C, Welte T. Bronchodilatatoren in der Dauertherapie der
chronisch-obstruktiven Lungenerkrankung (COPD). Med Klin (Munich) 2005;100(5):246-54.
95. Barnes PJ. The pharmacological properties of tiotropium. Chest 2000;117 Suppl 2:S63-6.
96. Calverley PM. The future for tiotropium. Chest 2000;117 Suppl 2:S67-9.
97. Vincken W, van Noord JA, Greefhorst AP, Bantje TA, Kesten S, Korducki L, Cornelissen PJ.
Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir
J 2002;19(2):209-16.
98. Casaburi R, Mahler DA, Jones PW, Wanner A, San PG, ZuWallack RL, Menjoge SS, Serby CW,
Witek T, Jr. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary
disease. Eur Respir J 2002;19(2):217-24.
99. Murciano D, Auclair MH, Pariente R, Aubier M. A randomized, controlled trial of theophylline in
patients with severe chronic obstructive pulmonary disease. N Engl J Med 1989;320(23):1521-5.
100. McKay SE, Howie CA, Thomson AH, Whiting B, Addis GJ. Value of theophylline treatment in patients
handicapped by chronic obstructive lung disease. Thorax 1993;48(3):227-32.
101. Cooper CB, Davidson AC, Cameron IR. Aminophylline, respiratory muscle strength and exercise
tolerance in chronic obstructive airway disease. Bull Eur Physiopathol Respir 1987;23(1):15-22.
102. Evans WV. Plasma theophylline concentrations, six minute walking distances, and breathlessness in
patients with chronic airflow obstruction. Br Med J (Clin Res Ed) 1984;289(6459):1649-51.
© 2006
84